NNRTIs in Development
- Lersivirine: 48-Week Results Compared to Efavirenz in Phase 2 Treatment-Naive Study (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- New Drug Adds to Arsenal Against AIDS (July 25, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- New NNRTI Lersivirine Looks Good in Phase 2 Study (July 21, 2011)
From HIVandHepatitis.com
- Non-Nuke Lersivirine Promising in First-Time Treatment Takers (July 19, 2011)
From AIDSmeds.com
- Non-Nucleoside Reverse Transcriptase Inhibitors in Development (May 21, 2011)
To read PDF, click here.
From AIDS InfoNet
- MSF Letter Criticizes Johnson & Johnson for Not Joining Medicines Patent Pool (April 26, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- ViiV/GSK NNRTI "761" Development Placed on Hold by FDA (February 16, 2011)
From Test Positive Aware Network
- GSK New NNRTI Selects No Resistance Mutations in 7 Days of Monotherapy (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC
- Two NNRTIs in Early Development Show Promising Results (August 7, 2008)
From Project Inform
- New Drugs From Old Classes (Spring 2006)
A listing of NNRTIs, NRTIs and protease inhibitors currently in development.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
- NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body
- BILR 355 BS, a Second-Generation NNRTI, Shows Activity Against Most Common NNRTI Mutations (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- GW695634 Demonstrates Potent Activity in 7-Day Monotherapy Study in an NNRTI Treatment-Experienced Population (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Pfizer Discontinues Development of Capravirine, for HIV/AIDS (July 1, 2005)
[Archived Article]
From Pfizer, Inc.
- Early Pre-Clinical Development of GW8248 Promising (September 14, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- New Anti-HIV Therapies: Other New NNRTIs (January 2003)
[Archived Article]
From Project Inform
- New Anti-HIV Therapies: Capravirine (January 2003)
[Archived Article]
From Project Inform
- New Anti-HIV Therapies: New NNRTIs (January 2003)
[Archived Article]
From Project Inform
- Non-Nucleoside Reverse Transcriptase Inhibitors (Summer/Autumn 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Experimental NNRTI Drugs (Spring 2001)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Pharmacokinetics of MKC-422, One of the Next Non-Nucleoside Reverse Transcriptase Inhibitors, Together With ZDV, 3TC, d4T, and ddI (June 29, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
|
Advertisement
|
Email
Glossary
